Guillain-Barré Syndrome Complications and Management

Introduction to Guillain-Barré Syndrome

Guillain-Barré Syndrome is dangerous primarily because approximately 20% of patients develop respiratory failure requiring mechanical ventilation, and autonomic dysfunction causes life-threatening cardiac arrhythmias and blood pressure instability, resulting in a 3-10% mortality rate even with optimal medical care 1, 2

The most critical danger in GBS is acute respiratory failure, which develops in about 20-30% of patients 1, 2
Rapid deterioration that can occur without obvious signs of respiratory distress, making clinical vigilance essential 1, 2
Patients are at imminent risk when vital capacity falls below 20 ml/kg, maximum inspiratory pressure is less than 30 cmH₂O, or maximum expiratory pressure is less than 40 cmH₂O 3
A single breath count of ≤19 predicts the need for mechanical ventilation 3

Autonomic nervous system involvement creates life-threatening cardiovascular instability 1, 2
Cardiac arrhythmias that can be fatal 1
Blood pressure instability ranging from severe hypertension to hypotension 2
These cardiovascular complications are particularly dangerous because they can occur unpredictably and require continuous cardiac monitoring 2

Most patients reach maximum disability within 2 weeks of symptom onset, making early recognition and treatment critical 1, 2
The window for effective immunotherapy is narrow (within the first 2 weeks) 1, 3
Despite advances in intensive care, the mortality rate remains 3-10% 1, 2, 3
Death primarily results from respiratory complications, including ventilator-associated pneumonia and respiratory failure 3
Cardiovascular complications from autonomic dysfunction 3
Advanced age and severe disease at onset as key risk factors 3

Only 60-80% of patients walk independently at 6 months 1
Treatment-related fluctuations occur in 6-10% of patients within 2 months of initial improvement, representing disease reactivation 1, 3

Delayed diagnosis due to variable clinical presentations and regional variants 2
Resource limitations in low- and middle-income countries, including limited ICU beds, ventilators, and access to immunotherapy, leading to higher mortality rates 4
Use of medications that worsen neuromuscular function (β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides) 3